Since inception, Coronado Biosciences has been a biopharmaceutical company involved in the development of novel immunotherapy agents for the treatment of autoimmune diseases and cancer, namely CNDO-201 or Trichuris suis ova (TSO) and CNDO-109. As part of its growth strategy, the Company plans to identify, evaluate and potentially in-license, acquire or invest in pharmaceutical and biotechnology products, technologies and/or companies. Coronado may also from time to time consider financing existing or later-acquired products, technologies or companies through partnerships, joint ventures, direct financings and/or public or private spin-outs.
October 8, 2014:
Coronado Biosciences Forms Subsidiary to Acquire and License Dermatology Products for Commercialization
August 11, 2014:
June 26, 2014:
May 14, 2014:
May 12, 2014:
May 9, 2014:All News
TSO (Trichuris suis ova or CNDO-201) is a biologic for the treatment of autoimmune diseases.
CNDO-109 is a biologic that activates natural killer (NK) cells for the treatment of acute myeloid leukemia (AML) and solid tumors.
ONGOING CLINICAL TRIALS
Click here for more clinical trial information.
Journey Medical Corporation